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Introduction 
Long-acting inhaled /&-agonists (LABS), used in conjunc- 
tion with low-dose inhaled steroids, are a recommended 
alternative to high-dose inhaled steroids for asthmatics with 
persistent symptoms (1). There are, however, few published 
data regarding their cost-effectiveness. The drugs are rela- 
tively expensive and the aim of this study was to evaluate 
LAB cost-effectiveness in primary care, in terms of 
improved clinical outcomes (associated with reduced NHS 
costs) offsetting higher prescription costs. A controlled, 
retrospective, non-randomized analysis utilized the compu- 
terized Thorpewood Primary Care Database and compared 
clinical outcomes and asthma management costs 1 yr prior 
to and 1 yr after initiation of therapy with salmeterol 
xinafoate. 
Patients and Methods 
Inclusion criteria for study group 
l Regularly monitored, confirmed diagnosis of asthma 
l Inhaled steroid therapy for at least 2 yrs prior to 
addition of salmeterol 
l No concomitant increase in inhaled steroid dosage with 
salmeterol therapy 
l Minimum of 1 yr salmeterol therapy 
Inclusion criteria -for control group 
As above except that patients had been prescribed sal- 
meter01 for less than 1 yr at the study date. The study group 
(n=23) were followed for consecutive years, immediately 
prior to (Year 1) and 1 yr into (Year 2) salmeterol therapy. 
A second group of patients (n= 14) who were prescribed 
salmeterol subsequent to the period of study were followed 
for the 2 yrs immediately preceding. At the end of Year 2 
their asthma status was likely to be similar to that of study 
group patients at the end of Year 1. This group was 
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included as a control for non-drug effects (e.g. changes in 
practice staff or clinical procedures) which can influence 
clinical outcomes and/or costs. Whilst not directly compar- 
able in terms of asthma severity, given the retrospective 
nature of the study, this second group of patients was 
considered the most apposite comparison with the 
salmeterol treatment group (2). Baseline demographic and 
clinical parameters were noted and the following clinical 
and economic endpoints determined: 
l peak expiratory flow (PEF); 
l drug requirements: inhaled steroids, short-acting rescue 
/&-agonists, courses of oral prednisolone, courses of 
antibiotics; 
l number/type general practice consultations: surgery 
(GP/nurse) and home visits (day/night); 
l hospital attendance: out-patient/admissions. 
Analysis 
Analyses were based on Year 1:Year 2 differences calcu- 
lated for each endpoint and within each patient. The 
Wilcoxon matched-pairs signed-rank test was used. All tests 
were two-sided. Comparisons were not made between groups 
as patients were not randomized and demographic details and 
asthma severity were not matched. 
Healthcare resource utilization and prescriptions 
were costed and mean total management costs (i.e. 
medication + other healthcare contacts - including GP and 
nurse visits, hospital referrals and admissions) calculated 
per patient, as well as the percentage difference between 
Year 1 and Year 2 costs. These were then compared 
descriptively. Sources for unit costs were generally based on 
practice/local authority estimates for 1994. 
Results 
BASELINE COMPARISONS 
The two groups were broadly similar in terms of asthma 
duration, smoking habits and reasons for initiating/ 
subsequently initiating salmeterol therapy. However, 
asthma severity and demographics were not matched. The 
mean age of the salmeterol group was 38 years, that of 
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FIG. 1. Outcomes - Year 1:Year 2 comparisons (O), Year 1; (W), Year 2. (a) Percentage predicted mean clinic peak flow. 
(b) Median daily rescue &agonist use. (c) Frequency of general practice consultations (GP+nurse). (d) Mean asthma 
management costs (U), Asthma medications; @), other asthma costs. Note: P-values are based on the individual patient 
changes from Year 1 to Year 2. 
the controls, 24 years. Gender mix (%M:F) was 5050 
(salmeterol) and (72:28) (controls). Median dosage of 
inhaled corticosteroid (BDP or equivalent) was 1600,~~g 
day ~ ’ (salmeterol) and 450 pg day - ’ (controls). 
OUTCOMES - YEAR 1:YEAR 2 COMPARISONS 
Changes in PEF, rescue &agonist use, frequency of 
consultations, and asthma management costs are illustrated 
in Fig. 1. In addition: 
l median inhaled corticosteroid dosage fell by 400,ug in 
the salmeterol group (P=O.OOOl), and increased by 
6OOpg in the control group (P=O.O02); 
l the median number of short courses of oral steroids 
prescribed fell from one to zero for the salmeterol group 
(P=O.OOS) and remained at zero for the controls 
(P= 1.00). The proportion of study group patients having 
zero courses doubled, from 39 to 78%; 
l the number of courses of antibiotics prescribed did not 
change significantly for either group (P= 1.00); 
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average total management costs per patient per annum 
increased by +2.9% (E15.98) for the salmeterol group [Fig. 
l(d)]. The control group was cheaper to manage through- 
out, but costs increased by 51% (g123.86). 
The small number of GP home visits, hospital referrals 
and admissions precluded statistical comparison, although 
costs associated with these contacts were captured in the 
total asthma management cost calculations. 
Discussion 
The addition of salmeterol therapy was associated with 
significantly enhanced asthma control in terms of the 
following endpoints: 
l lung function improved; 
l inhaled steroid requirement was reduced; 
l rescue medication use decreased; 
l exacerbations diminished (as evidenced by fewer courses 
of oral prednisolone); 
l GP/nurse surgery consultations were reduced. 
The effects of salmeterol therapy on the various clinical 
outcomes investigated are generally in agreement with those 
observed in larger, prospective studies: reduced inhaled 
steroid requirement (3), improved lung function (3-S) and 
symptom control (3,4) and a diminution in the frequency of 
exacerbations (5) have all been documented. What is harder 
to interpret from the results of this limited, retrospective 
study is whether the improvements in clinical outcomes 
observed are directly due to salmeterol therapy. It is, 
however, notable that many studies have confirmed that the 
dose-response curve for inhaled steroids may be very flat 
and that increasing the dose of inhaled steroid may not be 
associated with marked clinical improvement (6). This 
would help to explain why the large increase in manage- 
ment costs of the control group failed to ‘buy’ the clinical 
benefits associated with salmeterol therapy. GPs and nurses 
were trying to gain control of patients’ asthma (in terms of 
symptoms and quality of life) but were failing to do so, 
hence the increase in general practice consultations for 
controls in Year 2. Another possible reason for improve- 
ment in the salmeterol group might be that patients were 
more compliant with their new combined therapy, however, 
compliance effects are likely to be transient and no change 
in repeat prescriptions (a measure of compliance) was 
noted. 
The increase in average total costs per patient for 
salmeterol therapy was minimal (+ 2.9%, 515.98). Medica- 
tion costs increased, but were almost completely offset - 
primarily by large savings in consultations. Moreover, this 
minimal increase in outlay resulted in significant patient 
benefits. By contrast, increased average total spend per 
patient in the control group (+51%, 5123.86) bought no 
such improvements and reflected more frequent surgery 
visits and increased prescribing costs. The reduction in 
consultations associated with salmeterol treatment is par- 
ticularly significant when set against a trend towards 
increased consulting - for asthma in particular (7). 
Our results indicate that the introduction of salmeterol 
therapy into general practice has been cost-effective -with a 
minimal increase in expenditure buying significant patient 
benefits and reducing GP/nurse consultations. Notwith- 
standing the design limitations of this study, the results 
strongly suggest that a switch to salmeterol therapy is 
cost-effective for the primary care management of asth- 
matics who, despite being prescribed increasing doses of 
inhaled steroids, have persistent problems. 
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